Axonics Modulation Technologies Inc to Discuss the FDA Approval and Recent Business Developments Call Transcript
Good day, ladies and gentlemen, and welcome to the Axonics Corporate Update Conference Call. (Operator Instructions) And as a reminder, this call may be recorded.
I would now like to introduce your host for today's conference, Jill Bertotti, at W2O Group. Please go ahead.
Thank you, operator, and thank you, everyone, for joining the Axonics Corporate Update Conference Call. Joining in on the call today from Axonics are Raymond Cohen, Chief Executive Officer; Dan Dearen, President and Chief Financial Officer; Karen Noblett, Chief Medical Officer; and John Woock, Chief Marketing Officer. Ray will provide prepared remarks and commentary on FDA approval, U.S. commercial plans and the general business update, followed by a Q&A session in which the other key members will be available.
Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events, prospects or performance are forward-looking statements as defined under
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |